27T51 + cemiplimab + bevacizumab

**27T51 + cemiplimab + bevacizumab** is an experimental combination therapy regimen for advanced solid tumors. It consists of three agents: - **27T51:** Not enough public clinical information is available for this agent; presumed to be an experimental anticancer molecule under investigation. - **Cemiplimab:** A fully human IgG4 monoclonal antibody that targets and inhibits the programmed death 1 receptor (PD-1), resulting in immune checkpoint inhibition and antitumor immune activation. Primarily developed for the treatment of various advanced cancers including cutaneous squamous cell carcinoma and recurrent/metastatic cervical cancer. - **Bevacizumab:** A recombinant humanized IgG1 monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), suppressing tumor angiogenesis and growth. Used widely for multiple solid tumors, including cervical cancer, colorectal cancer, and non-small cell lung cancer. No confirmed clinical data or regulatory approval exists for this specific three-drug combination. Available literature cites clinical use and investigations of cemiplimab plus bevacizumab (often with chemotherapy) in various advanced cancers, supporting the rationale for their combination. The primary mechanism is to combine immune checkpoint inhibition (cemiplimab), antiangiogenic therapy (bevacizumab), and potentially an investigational agent (27T51) to enhance antitumor efficacy.

Other names

REGN2810REGN-2810REGN 2810CEMICEMIPLIMAB-RWLC